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Abstract: The tyrosine kinase inhibitor crizotinib is an effective 
therapy for patients with cancers harboring rearrangements of the 
anaplastic lymphoma kinase (ALK) gene. Here, we describe two 
patients with advanced ALK-positive lung cancer who developed 
hypersensitivity to crizotinib, requiring temporary discontinuation of 
the drug. Both patients were treated with a rapid oral desensitization 
protocol allowing them to resume crizotinib without further signs or 
symptoms of hypersensitivity.
Key Words: Anaplastic lymphoma kinase, Crizotinib, 
Hypersensitivity, Desensitization.
(J Thorac Oncol. 2014;9: 1726–1728)
About 3–7% of nonsmall cell lung cancers (NSCLC) harbor chromosomal rearrangements that result in activation of ana-
plastic lymphoma kinase (ALK).1,2 Crizotinib, a small molecule 
tyrosine kinase inhibitor of ALK, ROS1, and MET, is associ-
ated with high response rates (~60%),3 prolonged progression-
free survival (PFS), and superiority to chemotherapy in patients 
with advanced ALK-positive lung cancer.4–6 Most side effects 
of crizotinib are mild and manageable. Common grade 1/2 side 
effects include visual disturbance (incidence 60%), diarrhea 
(60%), nausea (55%), vomiting (47%), constipation (42%), 
edema (31%), and fatigue (27%). Rash has been observed in 
only approximately 9% of crizotinib-treated patients7 and there 
have been no reported cases of grade 3/4 rash.8 Grade 3/4 
adverse events are less common and include increased alanine 
aminotransferase (17%), increased aspartate aminotransferase 
(9%), and neutropenia (12%). Hypersensitivity reactions to 
crizotinib have not been reported.7
The National Cancer Center Network (NCCN) guide-
lines recommend crizotinib as first-line treatment for patients 
with advanced ALK-positive NSCLC. The next generation 
ALK inhibitor ceritinib was also recently approved in the 
United States for ALK-positive patients with disease progres-
sion on or intolerance to crizotinib. Because there are limited 
data on the benefit of ceritinib in crizotinib-naive patients or in 
other crizotinib-responsive cancers, such as those with ROS1 
rearrangements9 crizotinib may be the most effective treat-
ment option for many patients.
Hypersensitivity reactions to cancer therapies pose 
a particular challenge for patients if few other active drugs 
are available, but standardized 12-step rapid desensitization 
protocols have been developed as a safe method for achiev-
ing temporary tolerance to a variety of intravenous chemo-
therapy agents, including platinums, taxanes, anthracyclines, 
and monoclonal antibodies.10 Here, we report two cases of 
ALK-positive NSCLC patients who developed a hypersensi-
tivity reaction soon after starting crizotinib, necessitating dis-
continuation of this drug. Through the use of a rapid 12-step 
desensitization clinical protocol, crizotinib was successfully 
reintroduced with no additional symptoms concerning for a 
hypersensitivity reaction.
CASE 1
A 77-year-old female never smoker underwent left 
lower lobectomy for a stage IIB lung adenocarcinoma fol-
lowed by four cycles of adjuvant cisplatin and pemetrexed. 
About 18 months later, surveillance scans revealed enlarging 
mediastinal nodes and a new splenic lesion. An endobron-
chial biopsy of a subcarinal lymph node confirmed recurrent 
adenocarcinoma, and an EML4-ALK fusion was detected by 
FoundationOne testing. The patient was started on crizotinib 
250 mg twice daily for metastatic NSCLC.
The first two doses of crizotinib were well tolerated. 
Approximately 3 hours after the third dose of crizotinib, the 
patient developed pruritic urticarial lesions involving the torso 
and extremities. There were no other systemic symptoms asso-
ciated with the rash at that time. The lesions spontaneously 
resolved over the course of 2 hours without any intervention. 
The patient continued with the fourth dose of crizotinib, and 
within 4 hours she again developed an urticarial rash involv-
ing the face and trunk, as well as edema of the periorbital and 
perioral regions. The patient’s daughter administered 100 mg 
of diphenhydramine, and crizotinib was discontinued. Her 
swelling resolved over the next 24–48 hours. The patient had 
no prior history of urticaria, angioedema, or drug allergies. 
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Her other medications included lisinopril and esomeprazole, 
which she had been taking for over 5 years, and which she 
continued taking after the hypersensitivity reaction with no 
adverse events.
Due to concern over recurrent hypersensitivity reac-
tions with administration of crizotinib, and because no other 
Food and Drug Administration (FDA)-approved ALK inhibi-
tor was available at that time, the patient was referred to our 
hospital for further management. She was treated as an inpa-
tient with a 12-step oral desensitization clinical protocol as 
described in Table 1. In brief, the patient was given 10 mg of 
both loratidine and cetirizine the night before and the morn-
ing of desensitization. She was also given a dose of fexof-
enadine 180 mg before the start of desensitization. A total 
of 250 mg of crizotinib was given in 12 steps over 3 hours. 
The contents of crizotinib capsules were dissolved in sterile 
water and diluted to make three concentrations (0.05, 0.5, 
and 5 mg/ml). The desensitization started at 0.0625 mg with 
a doubling of each subsequent administration of crizotinib 
until a final dose of 125 mg was reached. After each step, the 
patient was observed for 15 minutes for evidence of a hyper-
sensitivity reaction. The patient tolerated this desensitization 
protocol well with no symptoms or signs of a hypersensitiv-
ity reaction. She then received a dose of 250 mg crizotinib 12 
hours after completion of desensitization, and she was con-
tinued on crizotinib 250 mg twice daily thereafter. Her first 
restaging scans after crizotinib showed a partial response 
with decreases in the size and 18F-fluorodeoxyglucose avid-
ity of mediastinal lymph nodes and the splenic metastasis 
(imaging not shown). Since completing the desensitization, 
she has continued crizotinib 250 mg every 12 hours without 
incident for 4 months.
CASE 2
A 45-year-old female never smoker presented with stage 
IV lung adenocarcinoma with metastases to the brain, liver, 
and bone. Owing to cerebral edema from her brain metastases, 
she was initially treated with glucocorticoids and then started 
on whole brain radiation therapy. After completion of radia-
tion, while on a dexamethasone taper, her tumor was found to 
have an ALK rearrangement by fluorescence in situ hybridiza-
tion, and she was started on crizotinib 250 mg twice daily.
Three days after she completed the course of steroids 
(on her 15th day of crizotinib), she developed an erythematous 
maculopapular rash on her trunk and extremities. Crizotinib 
was discontinued and the rash resolved over the course of 5 
days with the use of topical hydrocortisone as well as oral sol-
umedrol and diphenhydramine. After resolution of the rash, 
crizotinib was immediately reintroduced at a reduced dose 
of 200 mg twice daily. Within 12 hours of the first dose, she 
developed a pruritic, erythematous, raised rash over her entire 
body concerning for urticaria. There were no other systemic 
symptoms such as dyspnea, wheezing, tongue/lip swelling or 
abdominal pain. Crizotinib was again discontinued with rapid 
resolution of the rash. She had no history of urticaria, angio-
edema, or drug allergies. Her other medications included 
omeprazole, hydromorphone, oxycodone, lorazepam, and 
megestrol acetate.
The patient was then treated with two cycles of cisplatin 
and pemetrexed, but developed progressive disease. She was 
referred to our institution for further management and consid-
eration of a clinical trial with a next generation ALK inhibi-
tor. Because of abnormal liver function tests due to hepatic 
metastases, the patient was ineligible for a clinical trial, and 
crizotinib was the only FDA-approved ALK inhibitor avail-
able to her at that time. She was admitted to the hospital and 
treated with the desensitization clinical protocol described 
in Table 1. She tolerated desensitization well with no further 
signs or symptoms of a hypersensitivity reaction. She con-
tinued on crizotinib 250 mg twice daily for 1 week, but then 
developed rapid disease progression and was transitioned to 
comfort measures.
TABLE 1.  Crizotinib Desensitization Protocol
Dose Number
Crizotinib 
Concentration (mg/ml)
Time Observed  
After Each Dose (min) Volume (ml) Dose (mg) Cumulative dose (mg)
1 0.05 15 1.25 0.0625 0.06
2 0.05 15 2.5 0.125 0.19
3 0.5 15 0.5 0.25 0.44
4 0.5 15 1 0.5 0.94
5 0.5 15 2 1 1.94
6 5 15 0.4 2 3.94
7 5 15 0.8 4 7.94
8 5 15 1.6 8 15.94
9 5 15 3.2 16 31.94
10 5 15 6.25 31.25 63.19
11 5 15 12.5 62.5 125.69
12 5 15 25 125 250.69
Total time: 180 min
P.O., per os (orally).
Twelve hours before the first dose of crizotinib, administer loratidine 10 mg P.O. × 1 dose and cetirizine 10 mg P.O. × 1 dose.
One hour before the first dose of crizotinib, administer loratidine 10 mg P.O. × 1 dose, cetirizine 10 mg P.O. × 1 dose, and fexofenadine 180 mg P.O. × 1 dose.
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DISCUSSION
Small molecule kinase inhibitors have revolutionized 
the treatment and prognosis of many cancer types, but patients 
who develop hypersensitivity reactions to these agents are 
often unable to continue receiving these life-prolonging thera-
pies. Standardized desensitization protocols can overcome 
this therapeutic barrier by helping patients achieve temporary 
tolerance to drug allergens. In chronic myelogenous leuke-
mia, for example, a 4-hour oral desensitization protocol was 
used in 10 patients who had developed cutaneous drug reac-
tions to imatinib; eight were able to continue taking imatinib 
without recurrent rash or adverse events.11 In another case, a 
patient with BRAF V600E-mutant metastatic melanoma who 
developed Stevens-Johnson syndrome from vemurafenib was 
able to resume vemurafenib safely over the course of a 3-week 
desensitization program.12
Hypersensitivity reactions to crizotinib have not been 
previously reported. Crizotinib was granted accelerated 
approval by the U.S. FDA in 2011 and has been shown to be 
superior to standard chemotherapy in the first- and second-
line settings for ALK-positive NSCLC patients.4,5 Ceritinib 
was approved in 2014 for ALK-positive patients who are 
resistant to or intolerant of crizotinib.13 These two agents are 
currently the only two FDA-approved targeted therapies for 
patients with advanced ALK-positive NSCLC.
Although patients with crizotinib hypersensitivity can 
potentially be switched to ceritinib as an alternative ALK 
inhibitor, continuing crizotinib after desensitization may be 
a more preferable option for a variety of reasons. First, the 
sequencing of first-line crizotinib followed by ceritinib may 
potentially result in longer PFS compared with that afforded 
by upfront treatment with ceritinib. In the phase 1 study of 
ceritinib, median PFS among 34 patients who had not received 
crizotinib previously was 10.4 months,13 similar to that 
reported with first line crizotinib.5 Among patients who previ-
ously received crizotinib, median PFS with ceritinib was 6.9 
months.13 Thus, in theory, sequential therapy with crizotinib 
followed by ceritinib could lead to a “total” PFS of almost 
18 months. Second, crizotinib has a more favorable side 
effect profile than ceritinib, with milder gastrointestinal side 
effects7,14 and possibly less impact on daily functioning and 
overall quality of life. Finally, to date, hypersensitivity reac-
tions to ceritinib have not been observed, though rash has been 
reported in 16% of patients treated with ceritinib.14 Whether 
patients who develop hypersensitivity to crizotinib may be 
predisposed to hypersensitivity to ceritinib is unknown, but 
cross-reactivity to the two drugs is a theoretical possibility.
In this report, we describe the first cases of crizotinib 
hypersensitivity in two ALK-positive NSCLC patients. Both 
patients were able to safely resume the drug after being treated 
with a 12-step oral desensitization clinical protocol. With an 
increasing number of potent kinase inhibitors on the hori-
zon in oncology, desensitization procedures such as the one 
described here may be an important tool to allow patients to 
continue on effective targeted therapies for their cancers.
REFERENCES
 1. Soda M, Choi YL, Enomoto M, et al. Identification of the transform-
ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature 
2007;448:561–566.
 2. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and out-
come of patients with non-small-cell lung cancer who harbor EML4-
ALK. J Clin Oncol 2009;27:4247–4253.
 3. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhi-
bition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–1703.
 4. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in 
advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385–2394.
 5. Mok T, Kim D-W, Wu Y-L, et al. First-line crizotinib versus pemetrexed-
cisplatin or pemetrexed-carboplatin in patients (pts) with advanced 
ALK-positive non-squamous non-small cell lung cancer (NSCLC): 
results of a phase III study (PROFILE 1014). ASCO Meeting Abstracts. 
2014;32(Suppl 15):8002.
 6. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall 
survival in patients with advanced non-small-cell lung cancer harbour-
ing ALK gene rearrangement: a retrospective analysis. Lancet Oncol 
2011;12:1004–1012.
 7. Xalkori package insert 11/2013. Available at: http://www.xalkori.com/
sites/default/files/documents/Xalkori_PI.pdf.
 8. Xalkori package insert 2/2012. Available at: http://www.accessdata.fda.
gov/drugsatfda_docs/label/2012/202570s002lbl.pdf
 9. Ou S-HI, Bang Y-J, Camidge DR, et al. Efficacy and safety of crizotinib 
in patients with advanced ROS1-rearranged non-small cell lung cancer 
(NSCLC). ASCO Meeting Abstracts. 2013;31(Suppl 15):8032.
 10. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to 
chemotherapy: outcomes and safety of rapid desensitization in 413 cases. 
J Allergy Clin Immunol 2008;122:574–580.
 11. Nelson RP Jr, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD. 
Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma 
Immunol 2006;97:216–222.
 12. Minor DR, Rodvien R, Kashani-Sabet M. Successful desensitization in 
a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res 
2012;22:410–411.
 13. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-
small-cell lung cancer. N Engl J Med 2014;370:1189–1197.
 14. Zykadia package insert 4/2014. Available at: http://www.pharma.
us.novartis.com/product/pi/pdf/zykadia.pdf
